H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $123 from $110 and keeps a Buy rating on the shares. The firm says the company’s Prader-Willi syndrome proof-of-concept data demonstrates setmelanotide has a therapeutic impact. It nstituted forward sales forecasts for setmelanotide in PWS in the U.S. only, with a 60% probability of regulatory approval.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals Announces Resignation of Board Member Bedrosian
- Rhythm Pharmaceuticals price target raised to $140 from $120 at Guggenheim
- Rhythm Pharmaceuticals price target raised to $157 from $141 at Goldman Sachs
- Promising Clinical Results and Market Potential Drive Buy Rating for Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals price target raised to $141 from $114 at Canaccord